Flucostat caps. 50mg # 7

Dosage form

Capsules

Structure

pancreatin 25,000 IU (320 mg),

which corresponds to the activity:

lipases 25,000 units, amylases 19,000 units, proteases 1300 units

Excipients: microgranule shell: eudragit (E100) (methyl methacrylate, dimethylaminoethyl methacrylate and butyl methacrylate copolymer), triethyl citrate, talc, simethicone emulsion.

The composition of the capsule shell: gelatin, water, sodium lauryl sulfate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, dyes (Ponceau 4R, quinoline yellow, patented blue V, titanium dioxide).

pharmachologic effect

An enzyme preparation from the pancreas of animals, which includes protease, lipase and amylase, which ensure the digestion of proteins, fats and carbohydrates from food.

After taking the drug, the gelatin capsule under the action of gastric juice dissolves in the stomach and pancreatin microgranules, stable in the acidic environment of the stomach, together with the gastric contents enter the duodenum, and then into the small intestine, where the release of digestive enzymes occurs and enzymatic digestion of food is provided.

Pancreatin in the form of microgranules provides faster mixing of digestive enzymes with intestinal contents and their even distribution, which leads to higher digestive activity.

The enzymatic activity of pancreatin is manifested in a maximum of 30-40 minutes after ingestion.

Pharmacokinetics

After interacting with substrates, protease, lipase and amylase in the lower intestinal tract lose activity and, together with the intestinal contents, are excreted from the body.

The drug is not absorbed from the gastrointestinal tract and acts locally.

Side effects

Possibly: allergic reactions.

Rarely: when used in high doses - diarrhea, nausea, constipation, discomfort in the epigastric region.

With prolonged use in high doses: possible development of hyperuricosuria, hyperuricemia.

With cystic fibrosis, if the required dose of pancreatin is exceeded, strictures (fibrous colonopathy) may develop in the ileocecal part of the ascending part of the colon.

Selling features

Available without a prescription

Indications

Replacement therapy for exocrine pancreatic insufficiency:

- chronic pancreatitis

- cystic fibrosis

- pancreatic tumors

- surgical interventions on the pancreas.

Symptomatic therapy in complex treatment for the correction of disorders of the digestive process arising from other diseases or pathological conditions of the gastrointestinal tract:

- condition after resection of the stomach, gallbladder, part of the intestine

- diseases or conditions, accompanied by a violation of the process of bile secretion (liver disease, cholecystitis, gallstones, chronic diseases of the biliary tract, compression of the biliary tract by neoplasms, cystic growths)

- bowel diseases, accompanied by a violation of the movement of intestinal contents.

To improve the digestion of food in adults and children with normal gastrointestinal function when:

- errors in the diet (eating fatty foods or large amounts of food, irregular meals).

Contraindications

- acute pancreatitis

- exacerbation of chronic pancreatitis

- hypersensitivity to drug components.

Drug interactions

With the simultaneous use of pancreatin with iron preparations, a decrease in iron absorption is possible.

Dosage

Doses of the drug are selected individually, depending on the severity of the disease and diet.

If a single dose of the drug is more than 1 capsule, you should take half of the total number of capsules immediately before meals, and the other half during meals, washed down with a non-alkaline liquid (water, fruit juices).

If a single dose is 1 capsule, it should be taken with meals.

With difficulty swallowing and for

Name ENG

MIKRAZYM

Clinical and pharmacological group

Enzyme preparation

ATX code

Multienzymes (lipase, protease etc.)

Dosage

25000ED

Structure

Active ingredient: 25,000 IU of Pancreatin in the form of enteric pellets (microgranules). Excipients: pellet shell (microgranules): Eudragit E-100 (methyl methacrylate, dimethylaminoethyl methacrylate and butyl methacrylate copolymer), triethyl citrate emulsion capsicum, talcum shell composition water, sodium lauryl sulfate, methyl parahydroxybenzoate (methylparaben, nipagin), propyl parahydroxybenzoate (propylparaben)

dyes: crimson dye (Ponceau 4R), quinoline yellow dye, patented blue dye, titanium dioxide.

Indications

For replacement therapy for enzyme deficiency of the pancreas, associated with: hereditary diseases - cystic fibrosis (fibrosis of the pancreas), chronic pancreatitis pancreatic tumors surgical interventions on the pancreas. Replacement therapy for pancreatic enzyme deficiency cannot replace the treatment of the underlying disease.

Symptomatic therapy in complex treatment for correction of digestive disorders arising from other diseases or pathological conditions of the gastrointestinal tract: conditions after resection of the stomach, gallbladder, part of the intestine

diseases and conditions, accompanied by a violation of the process of bile secretion (liver disease, cholecystitis, gallbladder stones, chronic diseases of the biliary tract, compression of the biliary tract by neoplasms, cystic growths, etc.)

diseases of the small intestine and duodenum, large intestine, accompanied by a violation of the movement of intestinal contents.

To improve the process of food digestion in adults and children with normal gastrointestinal function in the case of:

inaccuracies in the diet (eating fatty and rough food, overeating, irregular eating)

with violations of chewing function, a sedentary lifestyle, prolonged immobilization.

For use in complex preparation for X-ray examination and ultrasound of the abdominal organs.

Storage conditions and periods

In a place protected from moisture and light, at a temperature not exceeding 25 degrees.

Expiration date: 2 years

Contraindications

Individual intolerance to pancreatin or individual components of the drug.

Acute pancreatitis, exacerbation of chronic pancreatitis.

INN / Active ingredient

pancreatin

Specifications

Category

Enzymes

,

Preparations for the gastrointestinal tract

Scope of the drug

Gastrointestinal tract

Release form

Capsules

Manufacturer country

Russia

Package quantity, pcs

fifty

Scope of application

Gastroenterology

Minimum age from

From birth

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

OTCPharm

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Digestive Enzyme Remedy

Anatomical and therapeutic characteristics

A09AA02 Polyenzyme preparations (lipase + protease, etc.)

Dosage form

Capsules

Packaging

Cardboard box

The target audience

Adult

Expiration date in days

730

Package weight, g

45

Mode of application

:

Doses of Micrasim are selected individually, depending on the severity of the disease and the composition of the diet. If a single dose of the drug is more than 1 capsule, you should take half of the total number of capsules immediately before meals, and the other half during meals, washed down with a non-alkaline liquid (water, fruit juices). < br> If a single dose is 1 capsule, it should be take with meals. If swallowing is difficult and for children, the capsule can be opened and the microgranules can be added to food that does not require chewing (eg applesauce, yogurt). Grinding or chewing microgranules, as well as adding them to food with a pH above 5.5, leads to the destruction of their shell, which protects against the action of gastric juice. The prepared mixture must be used immediately. During enzyme therapy, it is recommended to consume a sufficient amount of liquid,lack of fluid can cause constipation. < br> < br> Cystic fibrosis. The initial estimated dose for children of the first year of life and under 4 years of age is 1000 units of lipase per kilogram of body weight at each feeding, for children over 4 years of age - 500 units of lipase per kilogram at each meal. The dose should be selected individually, depending on the severity of the disease, the severity of steatorrhea and nutritional status. The maintenance dose for most patients should not exceed 10,000 IU of lipase per kilogram of body weight per day. < br> < br> Other types of exocrine pancreatic insufficiency. < br> When substitution therapy in patients with chronic pancreatitis, the dose of enzymes depends on the degree of exocrine insufficiency, as well as the individual dietary habits of the patient. With steatorrhea (more than 15 g of fat in feces per day),as well as in the presence of diarrhea and weight loss, when the diet does not give a significant effect, 25,000 units of lipase are prescribed at each meal. If necessary and well tolerated, the dose is increased to 30,000 - 35,000 U of lipase per dose. A further increase in the dose, in most cases, does not improve the results of treatment and requires a reconsideration of the diagnosis, a decrease in the fat content in the diet and / or additional prescription of drugs - proton pump inhibitors. With mildly pronounced steatorrhea, not accompanied by diarrhea and a decrease in body weight, from 10,000 to 25,000 IU are prescribed for admission Permissible dose for children: up to 1.5 years - 50,000 units per day for children over 1.5 years old, the daily dose of the drug should not exceed -100,000 IUwhen the diet does not give a significant effect, 25,000 units of lipase are prescribed at each meal. If necessary and well tolerated, the dose is increased to 30,000 - 35,000 U of lipase per dose. A further increase in the dose, in most cases, does not improve the results of treatment and requires a reconsideration of the diagnosis, a decrease in the fat content in the diet and / or additional prescription of drugs - proton pump inhibitors. With mildly pronounced steatorrhea, not accompanied by diarrhea and a decrease in body weight, from 10,000 to 25,000 IU are prescribed for admission Permissible dose for children: up to 1.5 years - 50,000 units per day for children over 1.5 years old, the daily dose of the drug should not exceed -100,000 IUwhen the diet does not give a significant effect, 25,000 units of lipase are prescribed at each meal. If necessary and well tolerated, the dose is increased to 30,000 - 35,000 units of lipase per dose. A further increase in the dose, in most cases, does not improve the results of treatment and requires a reconsideration of the diagnosis, a decrease in the fat content in the diet and / or additional prescription of drugs - proton pump inhibitors. With mildly pronounced steatorrhea, not accompanied by diarrhea and a decrease in body weight, from 10,000 to 25,000 IU are prescribed for admission Permissible dose for children: up to 1.5 years - 50,000 units per day for children over 1.5 years old, the daily dose of the drug should not exceed -100,000 IUdoes not improve the results of treatment and requires a revision of the diagnosis, a decrease in the fat content in the diet and / or additional prescription of drugs - proton pump inhibitors. With mildly pronounced steatorrhea, not accompanied by diarrhea and a decrease in body weight, from 10,000 to 25,000 IU are prescribed for admission Permissible dose for children: up to 1.5 years - 50,000 units per day for children over 1.5 years old, the daily dose of the drug should not exceed -100,000 IUdoes not improve the results of treatment and requires a revision of the diagnosis, a decrease in the fat content in the diet and / or additional prescription of drugs - proton pump inhibitors. With mildly pronounced steatorrhea, not accompanied by diarrhea and a decrease in body weight, from 10,000 to 25,000 IU are prescribed for admission Permissible dose for children: up to 1.5 years - 50,000 units per day for children over 1.5 years old, the daily dose of the drug should not exceed -100,000 IU5 years, the daily dose of the drug should not exceed -100,000 IU5 years, the daily dose of the drug should not exceed -100,000 U https://translate.google.com/translate?hl=&sl=ru&tl=en&u=https://zz.buy-pharm.com/xzzagrq.html;Description

pharmachologic effect

Flucostat is antifungal.

Selectively inhibits the synthesis of sterols in the cell wall of fungi.

Pharmacodynamics

Active against Candida spp., Cryptococcus neoformans, Microsporum spp., Trichoptyton spp., Blastomyces dermatitidis, Coccidioides immitis and Histoplasma capsulatum.

Pharmacokinetics

When taken orally, it is well absorbed in the digestive tract.

Cmax is reached within 0.5-1.5 hours after taking on an empty stomach.

It penetrates well into all body fluids, 6 months after completion of therapy it is determined in the nails.

Excreted by the kidneys up to 80%.

After intravenous administration, fluconazole penetrates well into tissues and body fluids.

Concentrations of the drug in saliva and sputum correspond to those in plasma.

In patients with fungal meningitis, the content of fluconazole in the cerebrospinal fluid reaches 80% of the corresponding plasma levels.

After several injections of 1 dose per day, 90% of the equilibrium concentration level is reached by the 4-5th day, with the introduction on the 1st day of a dose 2 times higher than the usual daily dose, by the 2nd day.

The apparent volume of distribution approaches the total volume of water in the body.

11-12% of fluconazole binds to plasma proteins.

T1 / 2 - 30 hours. Excreted by the kidneys 80% unchanged.

Fluconazole clearance is directly proportional to creatinine clearance.

No metabolites were found in the peripheral blood.

Indications

cryptococcosis, including cryptococcal meningitis and other localizations of this infection (including lungs, skin), both in patients with a normal immune response and in patients with various forms of immunosuppression (including AIDS patients, organ transplantation )

the drug can be used to prevent cryptococcal infection in AIDS patients

generalized candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis infections (infections of the peritoneum, endocardium, eyes, respiratory and urinary tract).

Treatment can be carried out in patients with malignant neoplasms, patients in intensive care units, patients undergoing cytostatic or immunosuppressive therapy, as well as in the presence of other factors that predispose to the development of candidiasis

candidiasis of the mucous membranes, incl.

oral cavity and pharynx (including atrophic candidiasis of the oral cavity associated with wearing dentures), esophagus, non-invasive bronchopulmonary candidiasis, candiduria, skin candidiasis

prevention of recurrence of oropharyngeal candidiasis in AIDS patients

genital candidiasis: treatment of vaginal candidiasis, prophylactic use in order to reduce the frequency of recurrence of vaginal candidiasis, candidal balanitis

prevention of fungal infections in patients with malignant neoplasms who are predisposed to such infections as a result of chemotherapy with cytostatics or radiation therapy

mycoses of the skin, including mycoses of the feet, body, groin

pityriasis versicolor, onychomycosis

candidiasis of the skin

deep endemic mycoses, including coccidioidomycosis, paracoccidioidomycosis, sporotrichosis and histoplasmosis in patients with normal immunity.

Contraindications

Hypersensitivity (including to azole compounds similar in structure), simultaneous use of terfenadine, astemizole, cisapride.

special instructions

In rare cases, the use of fluconazole was accompanied by toxic changes in the liver, incl.

with a lethal outcome, mainly in patients with serious concomitant diseases.

In the case of hepatotoxic effects associated with fluconazole, there was no clear dependence of them on the total daily dose, duration of therapy, gender and age of the patient.

The hepatotoxic effect of fluconazole was usually reversible

its signs disappeared after discontinuation of therapy.

If clinical signs of liver damage appear, which may be associated with fluconazole, the drug should be discontinued.

AIDS patients are more likely to develop severe skin reactions with many drugs.

In cases where patients with po

Name ENG

Flucostat

Clinical and pharmacological group

Mucolytic drug

Specifications

Category

Thrush

,

Antifungal

Scope of the drug

General

Release form

Capsules

Manufacturer country

Russia

Vacation conditions

Without recipe

Brand name

OTCPharm

Expiration date in days

1095

The target audience

Adult

Package weight, g

twenty

"